CURRICULUM VITAE

Name: **ZUO Joan Zhong**

Academic qualifications

B.Sc., Major in Pharmacy (1991): West China University of Medical Sciences, P. R. China

Ph.D. in Pharmaceutical Sciences (1998): University of Alberta, Canada

Previous academic poistions held:

Jan. 2000 to Aug. 2015:	Acting Director (2014), Professor (2009), Associate Professor (2004), Assistant Professor (2000), School of Pharmacy, The Chinese University of Hong Kong
Sept 1997 to Dec. 1999:	Scientist, Department of Biopharmaceutics and Pharmacokinetics, NAEJA Laboratories Inc., Edmonton, Canada
Aug. 1991 to Dec. 1992:	Industrial Pharmacist, Xian-Janssen Pharmaceutical Co. Ltd, P. R. China

Present academic positions: Professor (2009) and Director (2015), School of Pharmacy, The Chinese University of Hong Kong

Previous relevant research work: Biopharmaceutics and Pharmacokinetics

10 Selected publications (from five book chapters, 156 peer-reviewed journal papers and 178 abstracts, * as correspondence)

A) Five most representative publications in recent five years:

1. Yang MB, Zhang Q, Wang QW, Sørensen KK, Boesen JT, Ma SY, Jensen K, Kwan KM, Ngo JCK, Chan HYE & Zuo Z* (2018). Brain-targeting delivery of two peptidylic inhibitors for their combination therapy in transgenic polyglutamine disease mice via intranasal administration. *Molecular Pharm.* 15:5781-5792.
2. Fong YK, Li CR, Ho YC, Li R, Wang Q, Wong YC, Xue H, & **Zuo Z*** (2017). Brain Uptake of Bioactive Flavones in Scutellariae Radix and Its Relationship to Anxiolytic Effect in Mice. *Molecular Pharm.*14:2908–2916.
3. Zhu X, Deng JY, **Zuo Z**, & Lam TN* (2016). An Agent-Based Approach to Dynamically Represent the Pharmacokinetic Properties of Baicalein. *AAPS Journal* 18:1475-1488.
4. Fong Y K, Wong YC, Xie C, & **Zuo Z*** (2015). Herb-Drug Interactions between Scutellariae Radix and Mefenamic Acid: Simultaneous Investigation of Pharmacokinetics, Anti-Inflammatory Effect and Gastric Damage in Rats. *J. Ethnopharm*. 170:106–116.
5. Gao Q, Zhang YF, Wo SK, & **Zuo Z*** (2014). Elucidation of Arctigenin Pharmacokinetics After Intravenous and Oral Administrations in Rats: Integration of In Vitro and In Vivo Findings via Semi-mechanistic Pharmacokinetic Modeling. *AAPS Journal* 16:1321– 0 1333.

B) Five representative publications beyond the recent five-year period:

1. Lee LSN, Hui SCD, **Zuo Z,** Ngai LK, Lui CYG, Wo SK, Tam WSW, Chan CWM, Wong CKB, Wong YKR, Choi KW, Sin WYW, Lee LY, Tomlinson B, Hayden FG & Chan KSP (2013). A Prospective Intervention Study on Higher-dose Oseltamivir Treatment in Adults Hospitalized with Influenza A and B Infections. *Clinical Infectious Diseases* 57 (11): 1511–1519.
2. Li C, Zhang L, Zhou L, Wo SK, Lin G, & **Zuo Z*** (2012). Comparison of intestinal absorption and disposition of structurally similar bioactive flavones in radix scutellariae. *AAPS Journal* 14:23-34.
3. Zhang L; Li C, Lin G, Krajcsi P, & **Zuo Z*** (2011). Hepatic Metabolism and Disposition of Baicalein via the Coupling of Conjugation Enzymes and Transporters-In Vitro and In Vivo Evidences. *AAPS Journal* 13:378-389.
4. Sun HD, Zhang Li, Chow ECY, Lin G, **Zuo Z**, & Pang KS* (2008). A catenary model to study transport and conjugation of baicalein, a bioactive flavonoid, in the Caco-2 cell monolayer: demonstration of substrate inhibition. *J. Pharm. Exp. Ther.* 326:117-126.
5. Zhang L, Lin G, Kovács B, Jani M, Krajcsi P, & **Zuo Z*** (2007). Mechanistic study on the intestinal absorption and disposition of baicalein. *Eur. J. Pharm. Sci*. 31:221-231.

Patents:

- Sing Sum Moses Chow, Yan-feng Wang, & **Zhong Joan Zuo**. "Method of enhancing absorptions of transmucosal administration formulations", **USA Patent No.** US 7,329,416 B2, granted on Feb. 12, 2008; **Chinese Patent No.** 200580030149.3, granted March 24, 2010; Hong Kong Patent No. HK1107271, granted on May 31, 2010; Malaysian Patent No. MY-141878-A, granted on July 16, 2010.
- Sing Sum Moses Chow, Yan-feng Wang, & **Zhong Joan Zuo**. Method of enhancing absorptions of transmucosal administration formulations. Cont.-in-part of US 7,329,416 B2. USA Patent No.: 8,012,503B2, Date of Approval Sept. 6, 2011.